Vaccine, Journal Year: 2024, Volume and Issue: 42(5), P. 1122 - 1135
Published: Jan. 22, 2024
Language: Английский
The Lancet Infectious Diseases, Journal Year: 2023, Volume and Issue: 24(4), P. 351 - 360
Published: Dec. 20, 2023
Language: Английский
Citations
50
Immunity, Journal Year: 2024, Volume and Issue: 57(3), P. 587 - 599.e4
Published: Feb. 22, 2024
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. Here, we analyzed the kinetics and durability of humoral responses SARS-CoV-2 infection vaccination using >8,000 longitudinal samples collected over a 3-year period in New York City. Upon primary immunization, participants with pre-existing mounted higher antibody faster achieved steady-state titers than naive individuals. Antibody were characterized by two phases: an initial rapid decay, followed stabilization phase very slow decay. Booster equalized differences concentration between without hybrid immunity, but peak decreased each successive antigen exposure. Breakthrough infections increased antibodies similar as additional vaccine dose Our study provides strong evidence are long lasting, waning stabilization.
Language: Английский
Citations
43
Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 389 - 408
Published: March 15, 2024
Introduction Current vaccines vary widely in both their efficacy against infection and disease, the durability of efficacy. Some provide practically lifelong protection with a single dose, while others only limited following annual boosters. What variables make vaccine-induced immune responses last? Can breakthroughs these factors technologies help us produce better fewer doses? The is now hot area vaccinology research, especially after COVID-19 lost luster. It has fueled discussion on eventual utility existing to society bolstered anti-vaxxer camp. To sustain public trust vaccines, lasting must be developed.
Language: Английский
Citations
24
The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(4), P. 341 - 343
Published: Feb. 2, 2024
Language: Английский
Citations
19
The Lancet Infectious Diseases, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
2
Cellular and Molecular Immunology, Journal Year: 2023, Volume and Issue: 21(2), P. 103 - 118
Published: Dec. 26, 2023
Abstract Members of the coronaviridae family are endemic to human populations and have caused several epidemics pandemics in recent history. In this review, we will discuss feasibility progress toward ultimate goal creating a pan-coronavirus vaccine that can protect against infection disease by all members coronavirus family. We detail unmet clinical need associated with continued transmission SARS-CoV-2, MERS-CoV four seasonal coronaviruses (HCoV-OC43, NL63, HKU1 229E) humans potential for future zoonotic coronaviruses. highlight how first-generation SARS-CoV-2 vaccines natural history studies greatly increased our understanding effective antiviral immunity informed next-generation design. then consider ideal properties propose blueprint type may offer cross-protection. Finally, describe subset diverse technologies novel approaches being pursued developing broadly or universally protective
Language: Английский
Citations
31
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: March 6, 2024
Abstract There is a public health need to understand how different frequencies of COVID-19 booster vaccines may mitigate the risk severe COVID-19, while accounting for waning protection and differential by age immune status. By analyzing United States surveillance seroprevalence data in microsimulation model, here we show that more frequent vaccination (every 6–12 months) older groups immunocompromised population would effectively reduce burden boosters younger only provide modest benefit against disease. In persons 75+ years, model estimated annual absolute 199 (uncertainty interval: 183–232) cases per 100,000 persons, compared one-time vaccination. contrast, 18–49 this 14 (10–19) persons. Those with prior infection had lower boosting, larger benefit. Scenarios emerging variants evasion increased variant-targeted boosters. This study underscores considering key factors inform frequency guidance ensuring at least high-risk populations.
Language: Английский
Citations
15
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 24, 2024
Our understanding of COVID-19 vaccinations and their impact on health mortality has evolved substantially since the first vaccine rollouts. Published reports from original randomized phase 3 trials concluded that mRNA vaccines could greatly reduce symptoms. In interim, problems with methods, execution, reporting these pivotal have emerged. Re-analysis Pfizer trial data identified statistically significant increases in serious adverse events (SAEs) group. Numerous SAEs were following Emergency Use Authorization (EUA), including death, cancer, cardiac events, various autoimmune, hematological, reproductive, neurological disorders. Furthermore, products never underwent adequate safety toxicological testing accordance previously established scientific standards. Among other major topics addressed this narrative review are published analyses harms to humans, quality control issues process-related impurities, mechanisms underlying (AEs), immunologic basis for inefficacy, concerning trends based registrational data. The risk-benefit imbalance substantiated by evidence date contraindicates further booster injections suggests that, at a minimum, should be removed childhood immunization program until proper studies conducted. Federal agency approval blanket-coverage population-wide had no support an honest assessment all relevant commensurate consideration risks versus benefits. Given extensive, well-documented unacceptably high harm-to-reward ratio, we urge governments endorse global moratorium modified questions pertaining causality, residual DNA, aberrant protein production answered.
Language: Английский
Citations
13
Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: 13(1), P. 1 - 19
Published: Jan. 1, 2024
Despite the wide availability of effective vaccines, COVID-19 continues to be an infectious disease global importance. Remdesivir is a broad-spectrum antiviral and was first US Food Drug Administration-approved treatment for COVID-19. In clinical guidelines, remdesivir currently only recommended use in hospitalized patients with COVID-19, or without supplemental oxygen requirement. It also nonhospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are at high risk progression disease. This narrative review explores evidence across various outcomes evolution guidelines through survey over time randomized controlled trials, observational studies, meta-analyses. Remdesivir, compared standard care, appears improve survival variety patient populations spectrum severity SARS-CoV-2 variant periods. recovery, increase rate reduce on readmission rates. More recent large, real-world studies further support early range populations, including those immunocompromising conditions. When people get sick which caused by virus, may needed prevent serious illness. Studies have found that treating can save lives keep from getting sicker. help better faster, need less time, avoid having go back hospital. Newer treated settings, outside research environments, show likely many different groups patients, health conditions weaken their body's ability fight infection. Because this research, recommend should given some hospital stay other reasons but condition puts them
Language: Английский
Citations
12
Vaccine, Journal Year: 2024, Volume and Issue: 42(15), P. 3389 - 3396
Published: April 22, 2024
Language: Английский
Citations
9